item management s discussion and analysis of financial condition and results of operations 
except for the historical information contained herein  the matters discussed in this annual report on form k  including discussions of the company s product development plans  business strategies and market factors influencing the company s results  are forward looking statements that involve certain risks and uncertainties 
actual results may differ from those anticipated by the company as a result of various factors  both foreseen and unforeseen  including  but not limited to  the company s ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution  consolidation  and competition from larger  better capitalized competitors 
many other economic  competitive  governmental and technological factors could impact the company s ability to achieve its goals  and interested persons are urged to review the risks described in item business 
risk factors 
and in management s discussion and analysis of financial condition and results of operations 
set forth below  as well as in the company s other public disclosures and filings with the securities and exchange commission 
the following discussion should be read in conjunction with  and is qualified in its entirety by  the consolidated financial statements and related notes thereto included elsewhere herein 
historical results of operations  percentage margin fluctuations and any trends that may be inferred from the discussion below are not necessarily indicative of the operating results for any future period 
results of operations 
the following table sets forth for the periods indicated the percentage of net revenues represented by each item in the company s consolidated statements of operations 
the consolidated statements of operations include the operations of clinitec from may  the date of its acquisition through march  and the operations of micromed from may  the date of its acquisition through march  year ended march  net revenues sales of computer systems  upgrades and supplies maintenance and other services cost of products and services gross profit selling  general and administrative expenses research and development costs purchased in process research and development income loss from operations investment income income loss before provision for benefit from income taxes provision for benefit from income taxes net income loss for the years ended march  and the company incurred a net loss of million  or on a basic and diluted per share basis  for the year ended march  as compared to a net loss of million  or on a basic and diluted per share basis  for the year ended march  during fiscal  the company recognized a million charge  net of the related million tax benefit  for purchased in process research and development in connection with the micromed acquisition 
similarly  during fiscal  the company recognized an million charge  net of the related tax benefit  for purchased in process research and development in connection with the clinitec acquisition 
excluding the charge  net of the related income tax benefit  for purchased in process research and development  on a pro forma basis  net income and basic and diluted income per share for fiscal would have been million  and  respectively  and  and  respectively  for fiscal net revenues 
net revenues for the year ended march  increased to million from million for the year ended march  sales of computer systems  upgrades and supplies for the year ended march  increased to million from million for the year ended march  after the consolidation of micromed s net revenues in fiscal without the inclusion of micromed s revenues  the company s sales of computer systems  upgrades and supplies increased in fiscal as compared to fiscal net revenues from maintenance and other services during the year ended march  grew to million from million for the year ended march  resulting primarily from an increase in revenues from the company s larger client base for recurring maintenance and other services together with the consolidation of micromed s revenues in fiscal cost of products and services 
cost of products and services for the year ended march  increased to million from million for the year ended march  while costs of products and services as a percentage of net revenues decreased to from during the comparable periods 
the increase in the amount of costs of products and services during the year ended march  as compared to the year ended march  resulted primarily from increased systems sales and an increase in customer service  support  and training personnel during fiscal plus the addition of such costs for micromed s personnel 
the decrease in costs of products and services as a percentage of net revenues resulted primarily from the inclusion of micromed in fiscal to date  micromed s systems sales have not included any significant amount of hardware content 
systems sales without significant hardware content generally yield higher margins than systems sales that include a significant amount of hardware content 
the mixture of sales with and without significant hardware content fluctuates from period to period and there can be no assurance that the mixture of such sales attained in the year ended march   which contributed materially to the decrease in cost of products and services as a percentage of net revenues  will be achieved in future periods 
without the inclusion of micromed  costs of products and services increased in fiscal over fiscal and as a percentage of net revenues decreased to from 
the increase in the amount and decrease in percentage before the inclusion of micromed results primarily from higher systems sales 
selling  general and administrative expenses 
selling  general and administrative expenses for the year ended march  increased to million from million for the year ended march  representing and of net revenues  respectively 
the increase in selling  general and administrative expenses in both amount and as a percentage of net revenues is primarily the result of an increase in the company s selling efforts  including sales personnel  and administrative infrastructure together with the consolidation of micromed s selling  general and administrative expenses during fiscal without the inclusion of micromed s selling  general and administrative expenses  such expenses increased over fiscal and decreased to from as a percentage of net revenues 
before the inclusion of micromed  the increase in the amount of selling  general and administrative expenses resulted primarily from an increase in clinitec s selling efforts  including sales personnel  and administrative infrastructure together with a smaller increase in such costs for qsi 
research and development costs 
research and development costs for the year ended march  increased to million from million for the year ended march  primarily due to an increase in such efforts for qsi and clinitec together with the consolidation of micromed s research and development costs during fiscal research and development costs as a percentage of net revenues remained unchanged at for both periods 
without the inclusion of micromed  such costs increased and remained relatively unchanged at as a percentage of net revenues 
purchased in process research and development 
in connection with the acquisitions of micromed in may and clinitec in may  the purchase price allocated to in process research and development for which technological feasibility had not been established was million and million  respectively 
in accordance with statement of financial accounting standards no 
 accounting for the costs of computer software to be sold  leased or otherwise marketed  software development costs must be expensed until technological feasibility has been established 
accordingly  the purchase price allocated to in process research and development in each of fiscal and was expensed during the respective fiscal years 
investment income 
investment income for the year ended march  decreased to million from million for the year ended march  primarily as a result of a decrease in funds available for investment during fiscal after payment of the purchase price in connection with the company s micromed acquisition together with amounts used to fund the growth of clinitec and micromed 
provision for benefit from income taxes 
the benefit from income taxes for the year ended march  was million  resulting in an effective income tax rate of 
the provision for income taxes for the year ended march  was  and differs from the combined federal and state statutory rates primarily due to the non deductible charge for purchased in process research and development as well as non deductible amortization of certain intangibles acquired in the non taxable clinitec purchase transaction 
the micromed acquisition was a taxable transaction and  accordingly  the related purchased in process research and development is deductible for income tax purposes 
for the years ended march  and the company incurred a net loss of million  or on a basic and diluted per share basis  for the year ended march   as compared to net income of million  of per share and per share on a basic and diluted basis  respectively  for the year ended march  during fiscal  the company recognized an million charge  net of the related tax benefit  for purchased in process research and development in connection with the clinitec acquisition 
excluding the charge  net of the related income tax benefit  for purchased in process research and development  on a pro forma basis  net income and basic and diluted income per share for fiscal would have been  and  respectively 
there was no similar charge during fiscal net revenues 
net revenues for the year ended march  increased to million from million for the year ended march  sales of computer systems  upgrades and supplies for the year ended march  increased to million from million for the year ended march  after the consolidation of clinitec s net revenues in fiscal without the inclusion of clinitec s revenues  the company s sales of computer systems  upgrades and supplies declined in fiscal as compared to fiscal net revenues from maintenance and other services during the year ended march  grew to million from million for the year ended march  resulting primarily from an increase in revenues from the company s larger client base for recurring maintenance and other services together with the consolidation of clinitec s revenues in fiscal cost of products and services 
cost of products and services for the year ended march  increased to million from million for the year ended march  while costs of products and services as a percentage of net revenues increased to from during the comparable periods 
the increase in costs of products and services in both amount and as a percentage of net revenues during the year ended march  as compared to the year ended march  resulted primarily from increased customer service  support  and training personnel for qsi during fiscal plus the addition of such costs for clinitec s personnel 
the increase in the amount of costs of products and services also resulted from the higher net revenues attained in fiscal selling  general and administrative expenses 
selling  general and administrative expenses for the year ended march  increased to million from million for the year ended march  representing and of net revenues  respectively 
the increase in selling  general and administrative expenses in both amount and as a percentage of net revenues is primarily the result of the consolidation of clinitec s selling  general and administrative expenses during fiscal and amortization expense related to certain intangible assets acquired in connection with the clinitec acquisition during fiscal as well as higher selling  general and administrative expenses resulting from an increase in qsi s selling efforts  including sales personnel  and administrative infrastructure 
the increase in selling  general and administrative expenses as a percentage of net revenues between the comparable periods also resulted from the differing cost structure of clinitec as compared to qsi s cost structure prior to the acquisition as well as qsi s decrease in revenues before the inclusion of the clinitec revenues 
research and development costs 
research and development costs for the year ended march  increased to million from million for the year ended march  primarily due to the consolidation of clinitec s research and development costs during fiscal research and development costs as a percentage of net revenues remained relatively unchanged at and  respectively 
purchased in process research and development 
in connection with the acquisition of clinitec in may  clinitec s in process research and development for which technological feasibility had not been established was valued at million 
in accordance with statement of financial accounting standards no 
 accounting for the costs of computer software to be sold  leased or otherwise marketed  software development costs must be expensed until technological feasibility has been established 
accordingly  the value of the purchased in process research and development was expensed during the year ended march  there were no comparable transactions during the year ended march  investment income 
investment income for the year ended march  increased to million from  for the year ended march  primarily as a result of an increase in funds available for investment during fiscal arising from the company s million secondary public offering completed in march offset in part by funds used for the may clinitec acquisition 
provision for income taxes 
the provision for income taxes for the year ended march  was  and differs from the combined federal and state statutory rates primarily due to the non deductible charge for purchased in process research and development as well as non deductible amortization of certain intangibles acquired in the non taxable clinitec purchase transaction 
the provision for income taxes for the year ended march  was million  yielding a combined federal and state effective rate of which approximates the company s combined statutory rates for that period 
liquidity and capital resources 
net cash provided by operating activities was million   and million for the years ended march   and  respectively 
net cash provided by operations for the year ended march  consisted primarily of the company s net loss adjusted for the principal non cash operating expenses of depreciation  amortization and the million charge for purchased in process research and development incurred in connection with the acquisition of micromed together with decreases in deferred service revenue and other current liabilities offset in part by an increase in accounts receivable and deferred income tax benefits 
net cash provided by operations for the year ended march  consisted primarily of the company s net loss adjusted for the principal non cash operating expenses of depreciation  amortization and the million charge for purchased in process research and development incurred in connection with the acquisition of clinitec  offset by an increase in accounts receivable 
net cash provided by operations for the year ended march  consisted principally of net income before depreciation and amortization and an increase in accounts payable offset by an increase in accounts receivable 
the increase in accounts receivable during each of the fiscal years results primarily from increased sales and the timing of sales in each period 
net cash used in investing activities was million  million  and million for the years ended march   and  respectively 
net cash used in investing activities for the year ended march  was principally impacted by the million paid to acquire micromed during the year 
net cash used in investing activities for the years ended march  and was principally impacted by qsi s purchase of a ownership interest in clinitec for million in cash during fiscal and qsi s purchase of the remaining ownership interest during fiscal for million in cash and  shares of common stock 
net cash used for additions to equipment  improvements and capitalized software for the years ended march   and were million  million and  respectively  which were offset in part for the years ended march  and by cash provided from net sales of short term investments of  and  respectively 
there were no short term investment sales or purchases during the year ended march  net cash used in financing activities for the year ended march  was  consisting principally of  used to repurchase  shares of the company s common stock 
net cash provided by financing activities was  and million for the years ended march  and  respectively 
net cash provided by financing activities for the year ended march  consists of million of net proceeds from the company s march secondary public offering of one million shares of the company s common stock 
net cash provided by financing activities for the years ended march   and also includes the proceeds from the exercise of employee stock options 
at march   the company had cash and cash equivalents of million and short term investments of million 
short term investments include a  investment in a fund which trades in special situation securities 
there can be no assurance that the markets for these securities will not change  causing a loss of principal 
in march  qsi raised million to be used for general corporate purposes  including the financing of product sales growth  development of new products  working capital requirements  an increase in its ownership interest in clinitec see item business 
acquisitions  and the possible acquisitions of complementary businesses and technologies 
the company continues to evaluate potential investment opportunities and in may acquired substantially all of the assets of micromed see item business 
acquisitions 
for an initial cash payment of million with an additional payment of million due on or before june  the company anticipates that the additional payment will be made with million in cash with the balance to be paid in qsi common stock 
except for the acquisition of micromed and the company s intention to expend funds on capitalized software in connection with complementary products to its existing product line  alternative versions of certain of its products for the client server environment to take advantage of more powerful technologies and to enable a more seamless integration of the company s products  the company has no other significant capital commitments and currently anticipates that additions to equipment and improvements for fiscal will be comparable to fiscal the company believes that its cash and cash equivalents and short term investments on hand at march   together with the cash flows from operations  if any  will be sufficient to meet its working capital and capital expenditure requirements for the next year 
year compliance 
the company is aware of the issues associated with the programming code in existing computer systems as the millennium year approaches 
the year issue is whether the computer systems will properly recognize date sensitive information when the year changes to this year problem creates risk for the company from unforeseen problems in its own computer systems and from third parties with whom the company deals on financial transactions nationwide 
the company s windows product  nextgen and charting product are designed to be year compliant 
however  there can be no assurance that such products do not contain undetected errors or defects associated with year date functions 
the company is currently evaluating the impact of year issues upon its medical and dental legacy product software and  pending the conclusion of its evaluation  the impact of such year issues upon the company and its financial performance is uncertain 
the company has begun to review software used internally by the company in all support systems to determine whether they are year compliant 
the company plans to have formal year initiatives developed to address any conversion update or upgrade necessary to become year compliant on software currently used by the company 
any new software or support systems implemented in the future will be year compliant or will have updates or upgrades available before the year to enable the system to be year compliant 
management is currently assessing the year compliance expense and related potential effect on the company s earnings 
item a 
qualitative and quantitative disclosures about market risk 
not applicable 

